Piramal profits up 25% on domestic growth
This article was originally published in Scrip
Piramal Healthcare (previously Nicholas Piramal) has reported a 25% increase in net profits to Rs851 million ($17.6 million) for the first quarter ended June 30th, buoyed by strong growth in the domestic formulations business.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.